Key Highlights

  • Third-quarter 2026 net loss was USD 8.2 million, or USD 0.89 per share.
  • Research and development expenses were USD 6.7 million, against USD 9.8 million.
  • Working capital was approximately USD 41.8 million at September 30, 2026.
  • Existing cash and short-term investments are sufficient to fund operations through 2027, management states.

ProMIS Neurosciences (NASDAQ:PMN) reported a third-quarter 2026 net loss of USD 8.2 million, or USD 0.89 per share, against an estimate of a loss of USD 1.28 per share. The Nasdaq Capital Market-listed company is developing antibodies that selectively target misfolded toxic forms of proteins involved in neurodegenerative diseases. It reported no revenue.

Its product candidates are PMN310, a monoclonal antibody for Alzheimer's disease, PMN267 for amyotrophic lateral sclerosis and PMN442 for synucleinopathies such as dementia with Lewy bodies and Parkinson's disease.

Operating Results

Research and development expenses were USD 6,710,035 for the three months ended September 30, 2026, against USD 9,797,418 a year earlier. General and administrative expenses were USD 1,905,389, against USD 1,953,014. Total operating expenses were USD 8,615,424, against USD 11,750,432, and the loss from operations was the same USD 8,615,424, against USD 11,750,432.

Other income was USD 453,556, against USD 170,306. Net loss was USD 8,161,868, against USD 11,580,126, or USD 0.89 per basic and diluted share, against USD 5.93. Weighted-average common shares were 9,143,340, against 1,953,352.

For the nine months, Research and Development expenses were USD 23,202,834, against USD 24,011,452, and general and administrative expenses were USD 6,323,886, against USD 5,383,737. Net loss was USD 28,135,897, or USD 3.39 per share, against USD 29,045,059, or USD 19.58. The filing says other income rose by USD 1.0 million for the nine months because of higher interest income on higher cash balances following the January 2026 private placement, and that professional and consulting fees decreased by USD 0.4 million.

Liquidity and Funding

The filing reports an accumulated Deficit of USD 158.5 million at September 30, 2026, and negative operating cash flows of USD 32.1 million for the nine months, against USD 18.8 million of cash used in Operating Activities for the same period of 2025. Working Capital was approximately USD 41.8 million.

In January 2026, the company received net proceeds of USD 70.1 million from the sale of common shares, warrants and pre-funded warrants to external investors and certain directors and management in a private placement. Management states that, based on its current operating plan, existing cash and short-term investments are sufficient to fund operating expenses and Capital Expenditure requirements through 2027, while noting that this rests on assumptions that may prove wrong. It also states that it requires additional funding for future clinical activities and plans to seek it through public and private financings, debt financings, collaborations and licensing.

At September 30, 2026, there were 8,969,100 common shares outstanding, with 9,313,315 warrants and 1,052,439 Options outstanding, for a total of 19,334,896 common shares and equivalents.

Pipeline and Leadership

For PMN310, the filing says the company completed its single ascending dose Phase 1a trial and began the Phase 1b PRECISE-AD trial in December 2024. PRECISE-AD is a randomized, double-blind, placebo-controlled, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with early Alzheimer's disease. The FDA granted PMN310 Fast Track Designation in July 2025, and enrollment in the study was completed in December 2025.

In September 2026, the company entered into an employment agreement with Dr. Ivana Rubino, effective October 5, 2026, appointing her as Chief Commercial Officer.